AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Immunogen (IMGN) shares surge on news of takeover by AbbVie (ABBV)
November 30, 2023 9:09 AM ESTAbbVie (NYSE: ABBV) announced Thursday that it will acquire Immunogen (NASDAQ: IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.
The transaction values ImmunoGen at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.
Elahere... More
Sutro Biopharma (STRO) Trades Higher in Sympathy with Immunogen (IMGN)
November 30, 2023 7:45 AM ESTSutro Biopharma Inc. (NASDAQ: STRO) Trades Higher in Sympathy with Immunogen (NASDAQ: IMGN)
Earlier:
AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will... MoreImmunogen (IMGN) to Resume Trading at 8 a.m. Following News of Takeover by AbbVie (ABBV)
November 30, 2023 7:41 AM ESTImmunogen (NASDAQ: IMGN) to Resume Trading at 8 a.m. Following News of Takeover by AbbVie (NYSE: ABBV)
Earlier:
AbbVie Inc. (NYSE:... More